SLC5A2 and heart failure: Although SGLT2 inhibitors act in the kidney, natriuresis and osmotic diuresis reduce preload/afterload and improve cardio-renal outcomes; this mechanistic link explains heart failure approvals that extend beyond glycaemia (Vallon and Verma, 2021; Fathi et al., 2021).